Twist Bioscience prices $300M public offering at $96 per share

Twist Bioscience Corporation (Nasdaq: TWST) has priced an upsized underwritten public offering of 3,125,000 shares of common stock at $96.00 per share, according to a company statement.

The South San Francisco-based company expects gross proceeds of $300.0 million before underwriting discounts, commissions, and other offering expenses. Twist has also granted underwriters a 30-day option to purchase up to an additional 468,750 shares at the public offering price, less underwriting discounts and commissions.

The offering is expected to close on August 6, 2026, subject to customary closing conditions.

Twist said it intends to use the net proceeds, along with existing cash, cash equivalents, and marketable securities, to fund research and development, expand manufacturing capacity, broaden product offerings, and cover working capital and general corporate purposes.

Goldman Sachs & Co. LLC, William Blair, Leerink Partners, and Guggenheim Securities are serving as joint book-running managers for the offering.

The securities are being offered pursuant to an automatic shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on June 18, 2026.

You May Also Be Interested In

• Amylyx prices $500M stock offering at $35.50 per share
• Edesa Biotech launches public offering of common shares
• Singularity Future Technology closes $1.8M registered direct offering